Safety of segmental allergen challenge in human allergic asthma
Safety of segmental allergen challenge in human allergic asthma
复制标题
DOI：
10.1016/j.jaci.2007.08.058
复制
发表时间：
2008-03-01
影响因子：
14.2
通讯作者：
Virchow, Johann Christian
中科院分区：
文献类型：
--
作者：
Julius, Peter;Lommatzsch, Marek;Virchow, Johann Christian
背景：节段性变应原激发被广泛用于研究人类过敏性哮喘的机制。尽管相对较大的传播，有限的信息是可用的安全性，this method.Objective：观察性，回顾性研究报告的不良事件，在一个大的志愿者群体与asthma.Methods：在总数，78例从1994年至2007年之间进行的几项研究汇总为本次分析。志愿者接受过敏原激发，使用固定剂量的过敏原（7例）或单独标准化的过敏原剂量定义的吸入过敏原测试前的挑战（71例）。一个由13名志愿者组成的亚组接受了重复的过敏原激发，两次激发之间间隔超过6个月。结果：支气管镜检查期间滴注固定剂量的β 2受体激动剂后，43%的参与者出现喘息和咳嗽，在局部过敏原激发后需要2-6喷β 2受体激动剂。在接受单独标准化剂量的志愿者中，只有19%的病例需要使用β（2）激动剂。所有研究病例均未发生严重不良事件。志愿者谁经历了反复的挑战没有开发更多的不良事件比那些谁经历了1 challenge.Conclusions：节段性过敏原的挑战是一个安全的工具，研究人类过敏性哮喘的机制，即使在同一个病人进行反复的挑战。它只与少数可耐受的不良事件相关，特别是当过敏原的剂量单独标准化时。
Background: Segmental allergen challenge is widely used to study mechanisms of human allergic asthma. Despite the relatively large dissemination, limited information is available about the safety of this method.Objective: Observational, retrospective study to report the adverse events of segmental allergen challenge in a large group of volunteers with asthma.Methods: In total, 78 cases from several studies performed between 1994 and 2007 were pooled for this analysis. Volunteers underwent allergen challenge using either a fixed dose of allergen (7 cases) or an individually standardized allergen dose defined by an inhaled allergen test before the challenge (71 cases). A subgroup of 13 volunteers underwent repeated challenges, with more than 6 months between the challenges.Results: With a fixed dose instilled during bronchoscopy, 43% of the participants developed wheezing and coughing, requiring 2-6 puffs of a beta(2)-agonist after segmental allergen challenge. In volunteers with individually standardized doses, a beta(2)-agonist was required in only 19% of the cases. No severe adverse events occurred in all cases studied. Volunteers who underwent repeated challenges did not develop more adverse events than those who underwent 1 challenge.Conclusions: Segmental allergen challenge is a safe tool to study the mechanisms of human allergic asthma, even when repeated challenges are performed in the same patient. It is associated with only a few, tolerable adverse events, especially when the dose of allergen is standardized individually.